Home > Insider Trading > Filing (0000899243-22-029564)

Filing Details

Accession Number:: 0000899243-22-029564
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-08-23 20:19:16
Reporting Period:: 2022-08-19

Accepted Time:: 2022-08-23 20:19:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
895051	Casi Pharmaceuticals Inc.	CASI	Biological Products, (No Disgnostic Substances) (2836)	581959440

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1573160	James Huang	C/O Casi Pharmaceuticals, Inc. 9620 Medical Center Dr. Suite 300 Rockville MD 20850		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-08-19	171,116	$3.27	171,116	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2022-08-22	23,105	$3.46	194,221	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2022-08-23	40,000	$3.50	234,221	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	191	Direct

Footnotes

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.075 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.